TNF-alpha, Human, mAb 52B83,Hycult Biotech,HM2010

The monoclonal antibody 52B83 specifically targets tumor necrosis factor alpha (TNF-alpha), a crucial protein in immune responses and inflammation. TNF-alpha, a 17 kDa homotrimeric protein, interacts with TNF-receptors I and II, initiating varied cellular signaling pathways. Initially recognized for its anti-tumor effects, TNF-alpha destroys tumor cells both in vivo and in vitro, causing tumor necrosis and demonstrating cytolytic activity. Beyond its role in tumor biology, TNF-alpha stands at the center of many inflammatory and immunological processes. It responds to microbial products and other cytokines by triggering a broad cytokine response, illustrating its key position in inflammation. TNF-alpha’s pro-inflammatory actions are particularly significant in autoimmune diseases like rheumatoid arthritis. Neutralizing TNF-alpha has proven beneficial, offering therapeutic potential in such conditions. The 52B83 antibody’s interaction with TNF-alpha opens new avenues for treatment in autoimmune diseases, highlighting the importance of targeted therapies. This insight reinforces TNF-alpha’s vital role in immunology and inflammation research.